• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    BioOptics Stock Watch
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Teva Pharmaceutical Industries ADR (NY: TEVA )

    17.11 -0.39 (-2.23%)
    Official Closing Price Updated: 7:00 PM EST, Nov 8, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Teva Pharmaceutical Industries ADR

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    24 25 Next >
    Teva to Present at the Jefferies London Healthcare Conference
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    Teva Pharmaceutical Industries (TEVA) Q3 2024 Earnings Call Transcript
    TEVA earnings call for the period ending September 30, 2024. 
    Via The Motley Fool
    Topics Earnings
    Exposures Financial
    Generic Drug Maker Teva Clocks 13% Jump In Q3 Revenues, Tightens Annual Forecast
    Teva Pharmaceutical Industries Ltd (NYSE:TEVA) reported third-quarter 2024 sales of $4.33 billion on Wednesday. It beat the consensus of $4.12 billion. 
    Via Benzinga
    Teva Pharmaceutical Flashes A Buy Signal On Upbeat Third-Quarter Report
    The company also raised its outlook for the year. 
    Via Investor's Business Daily
    Teva Announces Strong Financial Results for the Third Quarter of 2024, led by Generics Performance and Innovative Portfolio Growth; Raises 2024 Financial Outlook including on Revenues, Adjusted EBITDA and Non-GAAP EPS
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,200 Today
    Via Benzinga
    A Closer Look at 4 Analyst Recommendations For Teva Pharmaceutical Indus
    Via Benzinga
    As Stock Market Awaits Election, Palantir, S&P 500 Nuke Leaders Report
    Amid the election, and a Fed rate vote, earnings season roars ahead. 
    Via Investor's Business Daily
    Topics Economy Stocks
    Exposures Interest Rates US Equities
    Teva Presents New Tardive Dyskinesia Data at Psych Congress 2024 from the IMPACT-TD Registry, Revealing Differences in Patient Experience Based on Underlying Psychiatric Condition
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    Teva Presents Latest Schizophrenia Treatment Research, Including Phase 3 SOLARIS Trial Results Demonstrating Improvements in Social Functioning and Quality of Life in Adults Receiving TEV-'749 (olanzapine) a Subcutaneous Long-Acting Injectable as well as
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    Teva Statement on European Commission Decision; Company to Appeal
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    Alvotech and Teva Announce U.S. FDA Approval of Additional Presentation of SELARSDI™ (ustekinumab-aekn), Expanding its Label to Include Further Indications Approved for Reference Product, Stelara® (ustekinumab)
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    Amicus Therapeutics Settles Patent Lawsuit Teva Pharmaceuticals Over Generic Version Of Its Rare Genetic Disorder Drug
    Amicus Therapeutics enters a license agreement with Teva Pharmaceuticals resolving patent litigation over a generic version of Galafold. Teva may market its version starting in 2037, pending FDA... 
    Via Benzinga
    Topics Intellectual Property Lawsuit
    Exposures Financial Intellectual Property Legal
    If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,400 Today
    Via Benzinga
    Teva Pays $450M To Resolve Alleged Kickback, Price-Fixing Schemes
    Teva Pharmaceuticals will pay $450 million to resolve allegations of kickback schemes involving Medicare copays and price-fixing. This settlement is part of a broader crackdown on healthcare fraud... 
    Via Benzinga
    Topics Fraud
    Exposures Legal
    Here's How Much $100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth Today
    Via Benzinga
    Teva Prolia® (Denosumab) Biosimilar Candidate is Accepted for Review by U.S. FDA and EU EMA
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected
    Guidance for the second cycle of Medicare drug price negotiations has expectations high for significant savings by 2026. 
    Via Benzinga
    Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candidate
    From Teva Pharmaceutical Industries Ltd; mAbxience
    Via GlobeNewswire
    Teva Launches Generic Version Of Sandostatin In The US
    Shares of Teva Pharmaceutical Industries (NYSE: TEVA) are down Tuesday. Here's what you need to know. 
    Via Benzinga
    Teva Announces Launch of the First and Only Generic Version of Sandostatin® LAR Depot (octreotide acetate for injectable suspension), in the U.S.
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    Teva to Host Conference Call to Discuss Third Quarter 2024 Financial Results at 8 a.m. ET on November 6, 2024
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    $1000 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth This Much Today
    Via Benzinga
    Corcept Therapeutics' Commercial Drug Korlym Sales Impress Despite Increased Competition, Analyst Boosts Price Forecast
    Truist Securities raises the price target for Corcept Therapeutics to $76, driven by robust Korlym sales and promising relacorilant trials. The analyst highlights significant growth potential in the... 
    Via Benzinga
    As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
    EQNX::TICKER_START (NASDAQ:NTRB),(NASDAQ:NTRBW),(NYSE:TEVA),(NYSE:LLY),(NYSE:NVS),(NASDAQ:AMRX) EQNX::TICKER_END 
    Via FinancialNewsMedia
    Exposures Product Safety
    As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
    From FN Media Group LLC
    Via GlobeNewswire
    Teva Announces Long Term Efficacy and Safety of Deutetrabenazine in European Patients with Debilitating Movement Disorder Tardive Dyskinesia
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000)
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    Teva to Present at the Bank of America 2024 Global Healthcare Conference
    From Teva Pharmaceutical Industries Ltd
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    24 25 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.